Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (94) clinical trials

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

The study has 2 parts: Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The ...


Patients are needed to participate in a clinical research study of paclitaxel, everolimus, ibrutinib, cetuximab, docetaxel

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.


A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally in continuous 28 day cycles. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Eligible subjects will be enrolled ...


A Phase 1b/2 Study of MEDI4736 With Tremelimumab MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma


A clinical trial seeking patients for a research study for the treatment of Renal Cell Carcinoma

A post marketing data collection of a cryosurgical system [PROSENSE] of IceCure Medical], for the treatment of renal cell carcinoma (RCC).


A Phase 3 clinical study for patients with Deleterious BRCA2 Gene Mutation, Recurrent Ovarian Carcinoma, Ovarian Seromucinous Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Endometrioid Tumor, Recurrent Fallopian Tube Carcinoma, BRCA Rearrangement, Ovarian Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Carcinoma, Ovarian Serous Tumor, Fallopian Tube Clear Cell Adenocarcinoma, Deleterious BRCA1 Gene Mutation

PRIMARY OBJECTIVES: I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer. SECONDARY OBJECTIVES: I. Assess ...


A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.


Study Of Gemcitabine Nab-paclitaxel PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 ...

Phase N/A

Patients are needed to participate in a clinical research study for the treatment of Colorectal Cancer, head and neck cancer, bladder cancer, Carcinoma, Squamous Cell of Head and Neck, Renal Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Adenocarcinoma

This is a phase 1, open-label, multicenter, dose escalation study that will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. The primary goal of the study is to identify the maximum tolerated dose (MTD), or optimal biological dose (OBD) that does not exceed the ...